Daniela Assisi

Daniela Assisi

Auto-generated profile, based on publicly available information

Daniela Assisi

Department of Gastroenterology Regina Elena National Cancer Institute, Rome, Italy

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2008 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
VSVittoria Stigliano
Vittoria Stigliano
DADaniela Assisi
Daniela Assisi
MCMaurizio Cosimelli
Maurizio Cosimelli
Raffaele PalmirottaRaffaele Palmirotta
Raffaele Palmirotta
DGDiana Giannarelli
Diana Giannarelli
VCVincenzo Casale
Vincenzo Casale
Patients with hereditary non-poliposys colorectal cancer (HNPCC) have better prognosis than sporadic colorectal cancer (CRC). Aim of our retrospective study was to compare the overall survival between sporadic CRC and HNPCC patients. We analyzed a cohort of 40 (25 males and 15 females) HNPCC cases with a hospital consecutive series of 573 (312 males and 261 females) sporadic CRC observed during the period 1970–1993. In 15 HNPCC patients we performed mutational analysis for microsatellite instability. Survival rates were calculated by Kaplan-Meier method and compared with log rank test. The median age at diagnosis of the primary CRC was 46.8 years in the HNPCC series versus 61 years in sporadic CRC group. In HNPCC group 85% had a right cancer location, vs. 57% in the sporadic cancer group. In the sporadic cancer group 61.6% were early-stages cancer (Dukes' A and B) vs. 70% in the HNPCC group (p = ns). The crude 5-years cumulative survival after the primary CRC was 94.2% in HNPCC patients vs. 75.3% in sporadic cancer patients (p < 0.0001). Our results show that overall survival of colorectal cancer in patients with HNPCC is better than sporadic CRC patients. The different outcome probably relates to the specific tumorigenesis involving DNA mismatch repair dysfunction.

19 February 2002
Verified
Journal Article
Closed access
CGC Greco
C Greco
SAS Alvino
S Alvino
SBSimonetta Buglioni
Simonetta Buglioni
DAD Assisi
D Assisi
RLR Lapenta
R Lapenta
VCV Casale
V Casale

8 February 2011 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
FPFrancesco Pisani
Francesco Pisani
CMCarlo Ludovico Maini
Carlo Ludovico Maini
RSRosa Sciuto
Rosa Sciuto
LDLaura Dessanti
Laura Dessanti
MDMariella D'Andrea
Mariella D'Andrea
MPMaria Concetta Petti
Maria Concetta Petti
This retrospective analysis is focused on the efficacy and safety of radioimmunotherapy (RIT) with Zevalin® in nine patients with recurrent follicular lymphoma (FL) who were treated in a consolidation setting after having achieved complete remission or partial remission with FCR.

30 January 2002
Verified
Journal Article
Closed access
MCM Crespi
M Crespi
VSV Stigliano
V Stigliano
DAD Assisi
D Assisi

1 March 1999
Verified
Journal Article
Closed access
PFP Fracasso
P Fracasso
DAD Assisi
D Assisi
VSV Stigliano
V Stigliano
VCV Casale
V Casale

30 September 2007 in Digestive and Liver Disease Supplements
Verified
Journal Article
Closed access
LML.S. Mete
L.S. Mete
DAD. Assisi
D. Assisi
VCV. Casale
V. Casale